Carasent Ab · OMXSTO:CARA
Carasent Ab — Q1 2026 Earnings Presentation
14 slides from Carasent Ab's earnings presentation, Apr 14, 2026
Slide 1: Interim report Q1
Interim report Q1 14 April 2026 Driving efficiency and quality in the world of care
Slide 2: Agenda
Agenda Todays presenters 1 Company update 2 Financial update Daniel Öhman Svein Martin Bjørnstad CEO CFO
Slide 3: Fast growing and highly recurring EHR business
Fast growing and highly recurring EHR business 3 344 349 LTM quarterly revenue 329 SEKm 311 Rapidly improving financials 294 275 240 245 250 254 261 360m 16% 20% 233 220 Contracted ARR Organic ARR EBITDA margin Q1 2026 growth Q1 2026 195 179 168 154 128 137 Sticky SaaS business model >90% 3% 111% Re
Slide 4: Highlights Q1
Highlights Q1 4 Update ▪ Good ARR growth and scalability ▪ Low consulting revenues ▪ First paying customer for Webcur – major milestone ▪ Promising traction for Medsum Growth ▪ Signed not implemented ARR amounts to SEK 4m ▪ 16% organic ARR growth and 7% reported organic growth Profitability ▪ EBITDA
Slide 5: AI update – how we act
AI update – how we act We reinvest AI-driven productivity gains to accelerate development, build best-in- class clinical AI support, and modernize the user experience Accelerated development ▪ We reinvest all AI productivity gains into faster product development, widening the gap to legacy systems a
Slide 6: AI Assistant for Clinical Documentation
AI Assistant for Clinical Documentation Seamlesssly integrated into the EHR – from conversation to completed chart 01 02 03 AI Outputs CAPTURE DETECT EXECUTE Clinical Notes Ambient Recording Action Recognition Auto-Draft & Fulfill Prescriptions Referrals The AI assistant records the Structured journ
Slide 7: Journey Ahead
Journey Ahead 7 Strong organic growth Efficient use of resources Launch Webcur Strong foundation of mission critical solutions with minimal churn in a growing and non-cyclical industry
Slide 8: Financial update Q1 2026
Carasent Capital Market Day 2023 Financial update Q1 2026
Slide 9: Carasent – Q1 financial highlights
Carasent – Q1 financial highlights 9 360 16% 20% Million contracted ARR per Q1 Organic ARR growth EBITDA margin 2026 (constant fx) 16% 111% 10% ARR growth Net retention rate EBITDA – capex margin
Slide 10: Strong improvements YoY
Strong improvements YoY 10 SEKm Q1 2026 Q1 2025 YoY growth 1▪ Growth affected by consulting revenues Subscription based 72.4 64.6 12 % Transaction based 14.0 12.6 11 % Consulting and other 4.0 8.0 -50 % 2▪ Gross profit back on stable levels Revenue 90.4 85.2 6% COGS -13.9 -13.2 Gross profit 76.5 72.
Slide 11: 16% organic ARR growth
16% organic ARR growth 11 Ending Q1 at a good pace with 16% organic ARR growth Implemented ARR Signed, not implemented ARR +36% vs 11m last year Boosted by large new units 360 4 10 15 320 45 -3% +5% 13 +15% 16% Q1’25 ARR (constant currency) Net upsale Churn New customers Q1’26 ARR
Slide 12: Scalability over time
Scalability over time 12 Keeping costs flat while growing revenues LTM development of cash cost base (adjusted for one-offs) LTM Revenue: 349m 245 243 236 231 231 229 229 234 234 231 229 Flat cost base Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 LTM revenues LTM o
Slide 13: Strong operating cash flow
Strong operating cash flow 13 SEKm Q1 2026 Q1 2025 FY 2025 FY 2024 ▪ Very strong working capital during Q1 2026, driven by certain effects: Revenue 90.4 85.2 343.8 275.3 ▪ Annual invoicing of certain Reported EBITDA 18.3 13.9 73.3 11.6 customers during Q1 Change in working capital 24.7 -9.4 -32.9 26
Slide 14: Q&A
Q&A